1
|
Murray CJ and Lopez AD: Mortality by cause
for eight regions of the world: Global Burden of Disease Study.
Lancet. 349:1269–1276. 1997. View Article : Google Scholar
|
2
|
Karadag F, Kirdar S, Karul AB and Ceylan
E: The value of C-reactive protein as a marker of systemic
inflammation in stable chronic obstructive pulmonary disease. Eur J
Intern Med. 19:104–108. 2008. View Article : Google Scholar : PubMed/NCBI
|
3
|
He Z, Chen Y, Chen P, Wu G and Cai S:
Local inflammation occurs before systemic inflammation in patients
with COPD. Respirology. 15:478–484. 2010. View Article : Google Scholar : PubMed/NCBI
|
4
|
Man SF, Connett JE, Anthonisen NR, Wise
RA, Tashkin DP and Sin DD: C-reactive protein and mortality in mild
to moderate chronic obstructive pulmonary disease. Thorax.
61:849–853. 2006. View Article : Google Scholar : PubMed/NCBI
|
5
|
Waschki B, Kirsten A, Holz O, et al:
Physical activity is the strongest predictor of all-cause mortality
in patients with chronic obstructive pulmonary disease: a
prospective cohort study. Chest. 140:331–342. 2011. View Article : Google Scholar : PubMed/NCBI
|
6
|
Celli BR, Cote CG, Marin JM, et al: The
body-mass index, airflow obstruction, dyspnea, and exercise
capacity index in chronic obstructive pulmonary disease. N Engl J
Med. 350:1005–1012. 2004. View Article : Google Scholar : PubMed/NCBI
|
7
|
Stolz D, Christ-Crain M, Morgenthaler NG,
et al: Copeptin, C-reactive protein, and procalcitonin as
prognostic biomarkers in acute exacerbation of COPD. Chest.
131:1058–1067. 2007. View Article : Google Scholar : PubMed/NCBI
|
8
|
Murphy SA, Haja Mydin H, Fatah S and
Antunes G: Predicting end-of-life in patients with an exacerbation
of COPD by routine clinical assessment. Respir Med. 104:1668–1674.
2010. View Article : Google Scholar : PubMed/NCBI
|
9
|
Lacoma A, Prat C, Andreo F, et al: Value
of procalcitonin, C-reactive protein, and neopterin in
exacerbations of chronic obstructive pulmonary disease. Int J Chron
Obstruct Pulmon Dis. 6:157–169. 2011.PubMed/NCBI
|
10
|
de Torres JP, Pinto-Plata V, Casanova C,
et al: C-reactive protein levels and survival in patients with
moderate to very severe COPD. Chest. 133:1336–1343. 2008.PubMed/NCBI
|
11
|
Liu SF, Wang CC, Chin CH, Chen YC and Lin
MC: High value of combined serum C-reactive protein and BODE score
for mortality prediction in patients with stable COPD. Arch
Bronconeumol. 47:427–432. 2011. View Article : Google Scholar : PubMed/NCBI
|
12
|
Miniati M, Monti S, Bottai M, Cocci F,
Fornai E and Lubrano V: Prognostic value of C-reactive protein in
chronic obstructive pulmonary disease. Intern Emerg Med. 6:423–430.
2011. View Article : Google Scholar : PubMed/NCBI
|
13
|
Man SF, Xing L, Connett JE, et al:
Circulating fibronectin to C-reactive protein ratio and mortality:
a biomarker in COPD? Eur Respir J. 32:1451–1457. 2008. View Article : Google Scholar : PubMed/NCBI
|
14
|
Rabe KF, Hurd S, Anzueto A, et al: Global
strategy for the diagnosis, management, and prevention of chronic
obstructive pulmonary disease: GOLD executive summary. Am J Respir
Crit Care Med. 176:532–555. 2007. View Article : Google Scholar : PubMed/NCBI
|
15
|
Dahl M, Vestbo J, Lange P, Bojesen SE,
Tybjaerg-Hansen A and Nordestgaard BG: C-reactive protein as a
predictor of prognosis in chronic obstructive pulmonary disease. Am
J Respir Crit Care Med. 175:250–255. 2007. View Article : Google Scholar : PubMed/NCBI
|
16
|
Cao C, Fang JJ, Ying T, et al: Vascular
endothelial growth factor +936C/T and +405G/C polymorphisms and
cancer risk: a meta-analysis. Arch Med Res. 41:548–557. 2010.
|
17
|
Cao C, Ying T, Fang JJ, et al:
Polymorphism of vascular endothelial growth factor -2578C/A with
cancer risk: evidence from 11263 subjects. Med Oncol. 28:1169–1175.
2011. View Article : Google Scholar : PubMed/NCBI
|
18
|
Parmar MK, Torri V and Stewart L:
Extracting summary statistics to perform meta-analyses of the
published literature for survival endpoints. Stat Med.
17:2815–2834. 1998. View Article : Google Scholar : PubMed/NCBI
|
19
|
Prescott E, Almdal T, Mikkelsen KL,
Tofteng CL, Vestbo J and Lange P: Prognostic value of weight change
in chronic obstructive pulmonary disease: results from the
Copenhagen City Heart Study. Eur Respir J. 20:539–544. 2002.
View Article : Google Scholar
|
20
|
Schembri S, Anderson W, Morant S, et al: A
predictive model of hospitalization and death from chronic
obstructive pulmonary disease. Respir Med. 103:1461–1467. 2009.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Coxson HO, Chan IH, Mayo JR, Hlynsky J,
Nakano Y and Birmingham CL: Early emphysema in patients with
anorexia nervosa. Am J Respir Crit Care Med. 170:748–752. 2004.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Cao C, Wang R, Wang J, Bunjhoo H, Xu Y and
Xiong W: Body mass index and mortality in chronic obstructive
pulmonary disease: a meta-analysis. PLoS One. 7:e438922012.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Nizet TA, van den Elshout FJ, Heijdra YF,
van de Ven MJ, Mulder PG and Folgering HT: Survival of chronic
hypercapnic COPD patients is predicted by smoking habits,
comorbidity, and hypoxemia. Chest. 127:1904–1910. 2005. View Article : Google Scholar : PubMed/NCBI
|
24
|
Nishimura K, Izumi T, Tsukino M and Oga T:
Dyspnea is a better predictor of 5-year survival than airway
obstruction in patients with COPD. Chest. 121:1434–1440.
2002.PubMed/NCBI
|